Sermorelin Before and After: Realistic Timeline by Month

Key takeaways

• There are no sermorelin before-and-after photos with controlled data behind them. What exists is three small 1990s trials in older adults that measured hormones, strength, body composition and skin at fixed time points; this page is built from those.
• Night one: a GH pulse within minutes, lasting about two hours. Weeks two to four: IGF-1 up (about 28% in the best trial) at studied doses of about 1 to 2 mg a day, but not at 0.5 mg twice daily, and not at 2 mg once nightly in one six-week trial.
• Week six: two of six strength measures improved in 11 older men; fat, muscle, weight and waist did not change. Week sixteen: skin thickness up in both sexes, lean mass up in men only, fat, weight and bone unchanged, IGF-1 drifting back toward baseline.
• Deeper sleep, more energy, glowing skin, fat loss and hair changes are reported by users and have no controlled data; the one sleep questionnaire in a trial showed no change.
• The before-and-after that matters is a lab result: IGF-1 at baseline and at 8 to 12 weeks. If it has not moved on a clinic dose of 200 to 500 mcg, the dose or the diagnosis deserves a second look.

Sermorelin before and after is usually a request for photos. None exist with controlled data behind them: no trial has photographed anyone, and clinic images come without doses, dates or any proof the person took sermorelin alone. What does exist is three small trials in older adults that measured specific things at specific weeks, and they answer the real question: what changes, when, and what never showed up. The parent GH secretagogue comparison puts sermorelin next to tesamorelin, ipamorelin and CJC-1295; the sermorelin dosage chart explains why the trial doses are three to ten times what clinics prescribe; the sermorelin profile has the evidence grading, side effects and legal status.

What before and after can mean for a hormone

Sermorelin does one thing directly: it makes the pituitary release a pulse of growth hormone. Everything else people hope for (IGF-1, muscle, fat, skin, sleep, energy) sits downstream, each step slower, smaller and less certain than the last. So the timeline has three layers: hormone changes measurable in days to weeks; tissue changes that took months to appear in trials, when they appeared at all; and subjective changes nobody has measured. One caveat covers the whole table: the longest adult trial used [Nle27]GHRH(1-29)-NH2, sermorelin with one amino acid swapped for stability, at 10 mcg/kg a night (about 0.7 to 0.9 mg), two to four times a typical prescription.

The timeline the trials support

Grades describe the evidence for an adult wellness user (editorial policy). Night 1, weeks 2 to 4, 8 to 12 and 16 come from the two reports of one 16-week trial (Khorram 1997) (Khorram 1997b); day 14 from (Corpas 1992); week 6 from (Vittone 1997); the pediatric data from the review of the former Geref label (Prakash & Goa 1999).

Month by month, in plain English

The first two weeks. The hormone response is immediate: a 9 pm injection produced a GH surge within about ten minutes, lasting about two hours, every night of the 16-week trial (Khorram 1997). You will not feel it; what people notice in week one are side effects, in the pediatric program transient facial flushing and injection-site pain (Prakash & Goa 1999). Dose decides everything from the start: after 14 days of 1 mg twice daily, older men had the GH and IGF-1 of men in their twenties, while 0.5 mg twice daily changed nothing significantly (Corpas 1992).

Month one. By week four IGF-1 was about 28% above baseline and overnight GH had roughly doubled in men and risen 70% in women (Khorram 1997b). That is the first measurable after, and schedule matters: 2 mg once nightly raised GH for six weeks without moving IGF-1, and the authors concluded that single nightly doses are less effective than multiple daily doses (Vittone 1997). Body composition changed in nobody.

Months two and three. The first non-hormonal signals, and they were small: at six weeks, two of six strength tests and one endurance test improved in 11 older men, with no change in DEXA fat or muscle, weight or waist (Vittone 1997). In the 16-week trial IGF-1 was still elevated at week 12 and blood pressure, weight, glucose and insulin were unchanged (Khorram 1997). This 8-to-12-week window is when the sermorelin hub's monitoring plan repeats IGF-1.

Month four. The only look at four months of nightly GHRH in adults: skin thickness by calipers up in both sexes; lean mass up in men but not women; fat mass, weight and bone density unchanged; insulin sensitivity, well-being and libido better in men only; sleep unchanged in both. And IGF-1, elevated for 12 weeks, was returning toward baseline by week 16 despite continued injections; the trial did not explain why (Khorram 1997).

After month four. No adult data. The pediatric program sustained height velocity over 12 months and in a few children 36 months (Prakash & Goa 1999), which says nothing about adult muscle, fat or skin. The ceiling is set by growth hormone itself in healthy older adults: about 2.1 kg less fat and 2.1 kg more lean mass over an average of 27 weeks, no change in weight, no functional benefit, and more edema, joint pain, carpal tunnel syndrome, gynecomastia and new diabetes (Liu 2007).

What people report that has no data

• Deeper sleep. No objective sleep study of sermorelin exists. GHRH given as small pulses in the first hours of the night increased deep and REM sleep in healthy volunteers (Marshall 1996); the one trial that asked people on a nightly GHRH analog about their sleep found no change over 16 weeks (Khorram 1997). Plausible, unproven.
• Energy. The nearest data are well-being questionnaires, better in men and not women at 16 weeks. One trial, one sex, one subjective scale.
• Skin. Caliper thickness increased at 16 weeks. A measurement, not a photo; nothing exists on wrinkles, tone or anything a camera shows.
• Fat loss. No adult trial found a change in fat mass, weight or waist. The GHRH analog with real visceral-fat data is tesamorelin.
• Hair, recovery, longevity, sermorelin with testosterone. Never measured; there is no trial of the testosterone combination, so a man on both cannot assign a result to either.

What before-and-after photos actually are

A photo pair proves that two photographs were taken. It cannot show the dose, the product, the timeframe or what else changed, and the sermorelin photos online usually come with none of that. Sermorelin is rarely sold alone: it arrives inside programs with testosterone, a GLP-1 drug, a blend with CJC-1295 or ipamorelin, or a diet and training plan, any of which can explain a photo by itself. The controlled evidence is clear on the one thing a photo claims to show: no trial found a change in fat mass at six weeks or sixteen. A clinic that leads with photos is showing you what it could not find in the literature.

Men versus women

Two of the three adult trials enrolled only men. In the third, GH and IGF-1 rose in both sexes, but lean mass, insulin sensitivity, well-being and libido improved in men only, skin thickness in both, and sleep in neither; the authors described the anabolic effects as favoring men (Khorram 1997). Sermorelin for women covers menopause, sleep and body composition; pregnancy and breastfeeding are reasons not to use it at all.

When to re-evaluate

Draw IGF-1, fasting glucose or HbA1c and a basic metabolic panel before the first dose, and repeat IGF-1 and glucose at 8 to 12 weeks; every trial that found a hormone effect showed it well before then. A rise in IGF-1 is the only objective sign the dose is doing its job. If it has not moved on a typical clinic dose, the suspects are the dose (three to ten times below the studied ones), the timing, the technique, or the diagnosis, since obesity, glucocorticoids and untreated thyroid disease blunt the response and a pituitary problem cannot be fixed from upstream. After that, every 3 to 6 months, with the same question each time: better by the lab and by the symptoms, or stop.

Bottom line

The honest sermorelin before and after is a lab report. GH rises the first night; IGF-1 rises within a month at about 1 to 2 mg a day; a few strength measures moved at six weeks; skin thickness and, in men, lean mass moved at four months; fat, weight, bone and sleep did not move; and nothing has been measured past four months, or at the doses most people are prescribed. Photos add nothing to that. An IGF-1 at baseline and at 8 to 12 weeks adds everything.

Frequently asked questions

+−How long does sermorelin take to work?

The growth hormone pulse comes within minutes of the first bedtime injection and lasts about two hours. IGF-1, the blood test that shows the pulse is doing something, rose within two to four weeks in the trials that used about 1 to 2 mg a day; it did not rise at 0.5 mg twice daily or, in one six-week trial, at 2 mg once nightly. Strength changes appeared at six weeks (two of six tests), lean mass and skin thickness at sixteen weeks, and no trial found fat loss at any point. Nobody has measured any of this at the 200 to 500 mcg doses most clinics prescribe.

+−Does sermorelin work?

It depends on what you mean by work. At 1 to 2 mg a day it reliably raises growth hormone in older adults and, on some schedules, IGF-1; that part is documented. The downstream results were modest and inconsistent: a couple of strength measures, lean mass in men only, thicker skin by calipers, no change in fat, weight or bone, and no change in sleep quality on questionnaires. Nothing has been measured at typical clinic doses, and no trial has tested it for aging, longevity or appearance. If an IGF-1 drawn 8 to 12 weeks in has not moved, it is not working for you at that dose.

+−What will sermorelin do to your body?

It signals the pituitary to release your own growth hormone in its normal pulse, mainly in the first hours of sleep, and the liver responds with more IGF-1. In the trials in older adults that is what reliably changed. Beyond the hormones, the measured effects over four months were an increase in skin thickness in both sexes and, in men only, more lean mass, better insulin sensitivity and better scores for general well-being and libido. Fat mass, weight, bone density and sleep did not change. The common side effects were injection-site reactions, facial flushing, headache and a transient rise in lipids.

+−Are sermorelin before and after photos real?

Some are real photographs; none are evidence. No trial has photographed anyone, and clinic photos come without the dose, the dates, a control, or any statement of what else the person was taking. Sermorelin is usually sold inside a program that can include testosterone, a GLP-1 drug, a blend with CJC-1295 or ipamorelin, and diet and training changes, any of which can explain a photo on its own. The trials that did measure body composition found no change in fat mass at six or sixteen weeks.

+−Does sermorelin change your face?

No trial has measured facial appearance. The one skin measurement in the literature is caliper thickness on the hands and forearm, which increased after sixteen weeks of a nightly GHRH analog in older adults. The facial changes people associate with growth hormone (a heavier jaw and brow) come from years of acromegaly-range levels, which a feedback-preserving secretagogue at studied doses does not produce. Photos claiming a changed face from sermorelin have nothing behind them.

+−Is sermorelin before and after different for women?

In the only adult trial that enrolled women, ten women and nine men aged 55 to 71 took the same weight-based dose for sixteen weeks. Growth hormone and IGF-1 rose in both sexes (GH by 70% in women and 107% in men), and skin thickness increased in both. Lean mass, insulin sensitivity, well-being and libido improved only in the men, and the authors described the anabolic effects as favoring men. There is no sermorelin trial in perimenopause or menopause, and it should not be used in pregnancy or while breastfeeding.

+−How long can you take sermorelin?

The adult trials ran 14 days, 6 weeks and 16 weeks; there are no longer adult safety data. The pediatric program followed children on the former Geref label for 12 months, with a few treated for 36 months. In the 16-week trial, IGF-1 had drifted back toward baseline by the end despite nightly injections, so a longer course is not obviously a stronger one. A reasonable plan is a baseline IGF-1 and glucose, a repeat at 8 to 12 weeks, then every 3 to 6 months, with a stop if the labs and the symptoms have not changed.

+−What happens when you stop sermorelin?

The overnight pulse stops the first night you skip it, because sermorelin is cleared in minutes. IGF-1 drifts back to baseline over weeks; in the 16-week trial it was already returning toward baseline during treatment. The trials did not report a rebound, a withdrawal syndrome or a crash in natural GH output afterwards, and because the drug works through your own pituitary with feedback intact, none is expected. Whatever strength or lean-mass change it produced is not locked in.

Sources

1. StudyCorpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and IGF-I levels in old men. J Clin Endocrinol Metab 1992;75:530-5. (1992)
2. StudyVittone J et al. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism 1997;46:89-96. (1997)
3. StudyKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]GHRH-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997;82:1472-9. (1997)
4. StudyKhorram O et al. Effects of [norleucine27]GHRH (1-29)-NH2 administration on the immune system of aging men and women. J Clin Endocrinol Metab 1997;82:3590-6. (1997)
5. ReviewPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999;12:139-57. (1999)
6. ReviewLiu H et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007;146:104-15. (2007)
7. StudyMarshall L et al. Greater efficacy of episodic than continuous growth hormone-releasing hormone (GHRH) administration in promoting slow-wave sleep (SWS). J Clin Endocrinol Metab 1996;81:1009-13. (1996)